These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27600985)

  • 1. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.
    Pascual J; Royuela A; Fernández AM; Herrero I; Delgado JF; Solé A; Guirado L; Serrano T; de la Torre-Cisneros J; Moreno A; Cordero E; Gallego R; Lumbreras C; Aguado JM;
    Transpl Infect Dis; 2016 Dec; 18(6):819-831. PubMed ID: 27600985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
    Bhat M; Watt KD
    Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M; Costa C; Solidoro P; Sidoti F; Libertucci D; Boffini M; Rinaldi M; Baldi S; Cavallo R
    Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature.
    Bowman LJ; Brueckner AJ; Doligalski CT
    Transplantation; 2018 Feb; 102(2S Suppl 1):S50-S59. PubMed ID: 29369973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.
    Brennan DC; Aguado JM; Potena L; Jardine AG; Legendre C; Säemann MD; Mueller NJ; Merville P; Emery V; Nashan B
    Rev Med Virol; 2013 Mar; 23(2):97-125. PubMed ID: 23165654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
    Andrassy J; Hoffmann VS; Rentsch M; Stangl M; Habicht A; Meiser B; Fischereder M; Jauch KW; Guba M
    Transplantation; 2012 Dec; 94(12):1208-17. PubMed ID: 23269449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
    Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
    Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and mTOR Inhibitors in Transplant Recipients.
    de Fijter JW
    Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P; Jouve T; Rostaing L
    Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
    Fisher RA
    Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.
    Sabé N; González-Costello J; Rama I; Niubó J; Bodro M; Roca J; Cruzado JM; Manito N; Carratalà J
    Transpl Int; 2012 Jul; 25(7):e78-82. PubMed ID: 22574951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
    Kowalsky S; Arnon R; Posada R
    Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous infections from viral sources in solid organ transplant recipients.
    Ilyas M; Maganty N; Sharma A
    J Clin Virol; 2017 Dec; 97():33-37. PubMed ID: 29096391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
    Holdaas H; Potena L; Saliba F
    Transplant Rev (Orlando); 2015 Apr; 29(2):93-102. PubMed ID: 25227328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.